PriceTargets.com logo

NASDAQ:MDWD - MediWound Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.50
  • Forecasted Upside: 49.40 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$5.02 As of 03/5/2021 01:00 AM ET
▼ -0.17 (-3.28%)
1 month | 3 months | 12 months
Get New MediWound Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDWD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDWD

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$7.50
▲ +49.40% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for MediWound in the last 3 months. The average price target is $7.50, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 49.40% upside from the last price of $5.02.
Buy
The current consensus among 4 investment analysts is to buy stock in MediWound. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/13/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/7/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/6/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/6/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/2/2021AegisInitiated CoverageBuy$10.00High
i
2/26/2021HC WainwrightBoost Price TargetBuy$5.50 ➝ $7.00High
i
9/23/2020BTIG ResearchInitiated CoverageBuy$6.00Medium
i
8/7/2020HC WainwrightReiterated RatingBuyMedium
i
Rating by S. Ramakanth at HC Wainwright
7/1/2020HC WainwrightReiterated RatingBuy$5.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/30/2020OppenheimerReiterated RatingBuy$7.00Low
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
5/21/2020HC WainwrightReiterated RatingBuy$5.50Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/18/2020OppenheimerInitiated CoverageBuy$7.00High
i
Rating by Kevin DeGeeter at Oppenheimer Holdings Inc.
1/7/2020HC WainwrightReiterated RatingBuy$5.50Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/15/2019HC WainwrightReiterated RatingBuy$5.50Medium
i
Rating by S. Ramakanth at HC Wainwright
8/14/2019OppenheimerLower Price TargetOutperform$15.00 ➝ $7.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/5/2019HC WainwrightInitiated CoverageBuy$5.50High
i
Rating by S. Ramakanth at HC Wainwright
3/25/2019OppenheimerSet Price TargetBuy$15.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
1/22/2019OppenheimerSet Price TargetBuy$15.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/14/2018OppenheimerSet Price TargetBuy$14.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/25/2018Wells Fargo & CompanySet Price TargetBuy$11.00Medium
i
Rating by David Maris at Wells Fargo & Company
9/24/2018OppenheimerSet Price TargetBuy$14.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/5/2018OppenheimerSet Price TargetBuy$14.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/8/2018Wells Fargo & CompanySet Price TargetBuy$11.00Medium
i
Rating by David Maris at Wells Fargo & Company
8/7/2018OppenheimerSet Price TargetBuy$14.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
6/11/2018OppenheimerSet Price TargetBuy$14.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
5/29/2018Wells Fargo & CompanyReiterated RatingBuyMedium
i
Rating by David Maris at Wells Fargo & Company
5/10/2018OppenheimerSet Price TargetBuy$14.00Medium
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/20/2018Wells Fargo & CompanyLower Price TargetOutperform ➝ Outperform$9.00 ➝ $8.00High
i
3/19/2018OppenheimerBoost Price TargetOutperform ➝ Outperform$10.00 ➝ $12.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
12/8/2017OppenheimerSet Price TargetBuy$10.00High
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
11/16/2017SunTrust BanksSet Price TargetBuy$9.00N/A
i
Rating by Bruce Nudell at SunTrust Banks, Inc.
11/16/2017OppenheimerSet Price TargetBuy$10.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
10/17/2017OppenheimerSet Price TargetBuy$10.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
9/28/2017CowenInitiated CoverageOutperform$9.00Medium
i
9/28/2017Jefferies Financial GroupReiterated RatingBuy$10.00Medium
i
Rating by Eun Yang at Jefferies Financial Group Inc.
9/18/2017OppenheimerReiterated RatingBuy$10.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
8/25/2017Jefferies Financial GroupSet Price TargetBuy$10.00High
i
6/26/2017SunTrust BanksReiterated RatingBuyLow
i
5/25/2017AegisReiterated RatingBuy$11.00Low
i
5/8/2017OppenheimerSet Price TargetBuy$10.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/22/2017OppenheimerReiterated RatingBuyHigh
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
3/8/2017OppenheimerReiterated RatingOutperform$10.00Low
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/9/2017OppenheimerSet Price TargetBuy$10.00N/A
i
Rating by Jay Olson at Oppenheimer Holdings Inc.
2/1/2017OppenheimerReiterated RatingOutperform$10.00N/A
i
11/28/2016AegisInitiated CoverageBuy$11.00N/A
i
8/17/2016Wells Fargo & CompanyInitiated CoverageOutperform$14.00N/A
i
7/29/2016Jefferies Financial GroupLower Price TargetBuy$15.00 ➝ $13.00N/A
i
4/23/2016Brean CapitalReiterated RatingBuyN/A
i
Rating by Jason Wittes at Brean Capital
3/23/2016SunTrust BanksInitiated CoverageBuy$13.00N/A
i
(Data available from 3/7/2016 forward)
MediWound logo
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Read More

Today's Range

Now: $5.02
$4.46
$5.28

50 Day Range

MA: $5.35
$4.40
$6.05

52 Week Range

Now: $5.02
$1.44
$6.07

Volume

235,780 shs

Average Volume

177,567 shs

Market Capitalization

$136.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63

Frequently Asked Questions

What sell-side analysts currently cover shares of MediWound?

The following sell-side analysts have issued research reports on MediWound in the last twelve months: Aegis, BTIG Research, HC Wainwright, Oppenheimer Holdings Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for MDWD.

What is the current price target for MediWound?

4 Wall Street analysts have set twelve-month price targets for MediWound in the last year. Their average twelve-month price target is $7.50, suggesting a possible upside of 49.4%. Aegis has the highest price target set, predicting MDWD will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $6.00 for MediWound in the next year.
View the latest price targets for MDWD.

What is the current consensus analyst rating for MediWound?

MediWound currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe MDWD will outperform the market and that investors should add to their positions of MediWound.
View the latest ratings for MDWD.

What other companies compete with MediWound?

Other companies that are similar to MediWound include Canopy Rivers, Charlie's, Natural Alternatives International, Nutra Pharma, Happiness Biotech Group, Glucose Health, True Drinks, Mannatech, FSD Pharma, FitLife Brands, Tauriga Sciences, Cyanotech, Heyu Biological Technology, GLG Life Tech and Exactus.

How do I contact MediWound's investor relations team?

MediWound's physical mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company's listed phone number is 972-8932-4010 and its investor relations email address is [email protected] The official website for MediWound is www.mediwound.com.